NASDAQ · PRAX
Healthcare · Biotechnology
$312.90
Down-$17.65 (-5.34%)
Updated Sep 16, 2026, 10:36 AM
SID Score
5.4/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PRAX closed at $312.90 after 20 trading sessions, down 15.40% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $330.42 | $333.061 | $311.98 | $312.90 | 205.66K |
| Sep 14, 2026 | $337.67 | $341.705 | $328.95 | $330.55 | 375.63K |
| Sep 11, 2026 | $340.00 | $348.00 | $334.00 | $334.58 | 175.41K |
| Sep 10, 2026 | $339.60 | $347.40 | $337.31 | $338.57 | 218.84K |
| Sep 9, 2026 | $352.80 | $360.6099 | $344.03 | $345.30 | 382.96K |
| Sep 8, 2026 | $342.25 | $356.29 | $339.50 | $352.48 | 252.62K |
| Sep 4, 2026 | $352.99 | $357.50 | $349.8182 | $351.81 | 175.36K |
| Sep 3, 2026 | $355.31 | $363.14 | $351.15 | $355.15 | 200.75K |
| Sep 2, 2026 | $358.42 | $365.71 | $347.0101 | $357.50 | 289.4K |
| Sep 1, 2026 | $350.00 | $355.4899 | $347.86 | $353.44 | 305.83K |
| Aug 31, 2026 | $343.00 | $351.715 | $333.46 | $350.30 | 380.66K |
| Aug 28, 2026 | $363.40 | $367.70 | $344.69 | $344.75 | 282.85K |
| Aug 27, 2026 | $375.77 | $377.50 | $366.875 | $367.85 | 242.88K |
| Aug 26, 2026 | $368.45 | $383.30 | $362.79 | $377.37 | 480.53K |
| Aug 25, 2026 | $374.10 | $382.378 | $361.985 | $368.02 | 294.33K |
| Aug 24, 2026 | $375.94 | $375.94 | $360.19 | $368.03 | 265.01K |
| Aug 21, 2026 | $370.35 | $387.99 | $365.37 | $375.94 | 413.32K |
| Aug 20, 2026 | $392.70 | $392.70 | $361.1616 | $364.58 | 496.67K |
| Aug 19, 2026 | $377.00 | $392.45 | $365.6401 | $386.19 | 421.8K |
| Aug 18, 2026 | $369.40 | $375.00 | $365.0501 | $369.84 | 255.85K |
The latest Smart Investors Daily articles mentioning PRAX.
PRAX research
Company profile and research snapshot.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2026 | Goldman Sachs | Buy | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 7, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 6, 2026 | Needham | Buy | — |
| Jul 29, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 12, 2026
Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and relutrigine. Click for more on PRAX.
Yahoo · Sep 3, 2026
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on September 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 11,535 shares of its common stock to sixty-six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan
Benzinga · Aug 21, 2026
Goldman Sachs analyst Kevin Strang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $470 to $575.
Yahoo · Aug 11, 2026
Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRAX.
